Abstract
The COVID-19 pandemic has been the most critical public health issue in modern his-tory due to its highly infectious and deathly potential; and the limited access to massive, low-cost, and reliable testing has significantly worsened the crisis. The recovery and the vaccination of millions of people against COVID-19, have made serological tests highly relevant to identify the presence and levels of SARS-CoV-2 antibodies. Due to its advantages, microfluidic-based technologies represent an attractive alternative to the conventional testing methodologies used for these purposes. In this work, we describe the development of an automated ELISA on-chip capable of detecting anti-SARS-CoV-2 antibodies in serum samples from COVID-19 patients and vaccinated individuals. The colorimetric reactions were analyzed with a microplate reader. No statistically significant differences were observed when comparing the results of our automated ELISA on-chip against the ones obtained from a traditional ELISA on a microplate. Moreover, we demonstrated that it is possible to carry out the analysis of the colorimetric reaction by performing basic image analysis of photos taken with a smartphone, which constitutes a useful alternative when lacking specialized equipment or a laboratory setting. Our automated ELISA on-chip has the potential to be used in a clinical setting and mitigate some of the burden caused by testing deficiencies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures involving human participants were performed in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Blood samples were collected according to the protocol approved by the Institutional Review Board of the Alfa Medical Center with number AMCCI-TECCOVID-001
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ever{at}delee.bio (E.G.-G.); ricardo{at}delee.bio (R.G.- R.); gladys{at}delee.bio (G.G.D.-A.); caguilar{at}delee.bio (C.A.-A.); miguel.esparza{at}delee.bio (M.E.); rolandodelga-do{at}delee.bio (J.R.D.-B.); brenda{at}delee.bio (B.S.-G.); diana{at}delee.bio (D.A.-H.); marisol{at}delee.bio (M.A.-B.); jose.yee{at}delee.bio (J.R.Y.-d.L.); liza{at}delee.bio (L.P.V.-C.); alejandro{at}delee.bio (A.A.-B.); juan.felipe{at}delee.bio (J.F.Y.-d.L.)
e.gzz{at}tec.mx (E.G.-G.)
eldafc92{at}gmail.com (E.A.F.-C.)
iram.rodriguezsa{at}uanl.edu.mx (I.P.R.-S.)
Data Availability
We reported the results in this manuscript